PANEL: STUDY METHOD AND RESULTS

摘要

Data from 1966 to 2010 was searched. This threw up 16 trials involving 10,217 patients with a range of advanced solid tumours. A total of 5,589 were available for analysis and 148 patients had fatal adverse events (FAEs).The overall incidence of FAEs with bevacizumab was 2.5 per cent (95 per cent confidence interval 1.7 per cent-3.9 per cent). Compared with chemotherapy alone, the addition of bevacizumab was associated with an increased risk of FAEs, with a relative risk of 1.46 (CI 1.09-1.94; P=0.01; incidence 2.5 per cent versus 1.7 per cent).